ARCHIVES

BMS Settles Charges Of Obstructing Generics

This article is from The Cancer Letter archive.

Vol. 29 No. 11 | March 14, 2003

Download PDF Visit The Full Archive

Related Articles

Letter to the Editors: Since 1992, Where Has All The OAM Grant Money Gone?

April 24, 1998

NCI Channels More Money To CIS, 17 Offices Funded

March 9, 1990

Trial Data: No Benefit In Adding Perifosine to Capecitabine

June 29, 2012

Funding Opportunities: RFA Available: Teams For Molecular Target Assessment

November 26, 1999

An Early Look At How NCI Plans To Spend Its Money In 1980

July 7, 1978

Doxil/Caelyx Survival 3 Weeks Longer Than Topotecan

November 28, 2003